Efficacy and Tolerance of Interferon β Plus Ribavirin Treatment for Chronic Hepatitis C Patients with Depression or Thrombocytopenia Comparison with Pegylated Interferon α Plus Ribavirin Treatment

Ikezaki, Hiroaki; Furusyo, Norihiro; Ogawa, Eiichi; Shimizu, Motohiro; Hiramine, Satoshi; Ura, Kazuya; Mitsumoto, Fujiko; Takayama, Kouji; Toyoda, Kazuhiro; Murata, Masayuki; Hayashi, Jun

doi:10.4172/2167-0889.1000155

Cited by 1 publication

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The favorable influence of IFN‐β on platelet count may partially explain this result. We have reported that the platelet count increased during IFN‐β plus RBV treatment . Previous studies have correlated a lowered platelet count with the development of HCC, therefore, an increase of platelet count may be favorable for preventing the development of HCC.…”

Section: Discussionmentioning

confidence: 82%

“…We have reported that the platelet count increased during IFN-β plus RBV treatment. 10 Previous studies have correlated a lowered platelet count with the development of HCC, 28,29 therefore, an increase of platelet count may be favorable for preventing the development of HCC. Thus, we believe that IFN-β plus RBV treatment is beneficial for patients with thrombocytopenia who have advanced fibrosis and thus are at risk for the development of HCC.…”

Section: E178mentioning

confidence: 99%

“…Although there is much evidence of an antitumor effect of pegylated (PEG) IFN‐α‐based treatment, limited data is available about the antitumor effect of IFN‐β‐based treatment . IFN‐β plus ribavirin (RBV) combination treatment has been an approved treatment for chronic hepatitis C by the Japanese Ministry of Health, Labour and Welfare, and some studies have shown that IFN‐β plus RBV treatment has equivalent efficacy and milder adverse effects than PEG IFN‐α plus RBV combination treatment . We previously reported that IFN‐β has a greater antitumor effect than IFN‐α, both in vitro and in vivo …”

Section: Introductionmentioning

confidence: 99%

“…[7][8][9] IFN-β plus ribavirin (RBV) combination treatment has been an approved treatment for chronic hepatitis C by the Japanese Ministry of Health, Labour and Welfare, and some studies have shown that IFN-β plus RBV treatment has equivalent efficacy and milder adverse effects than PEG IFN-α plus RBV combination treatment. [10][11][12] We previously reported that IFN-β has a greater antitumor effect than IFN-α, both in vitro and in vivo. [13][14][15] The primary aim of this retrospective, multicenter study was to evaluate the impact of IFN-β plus RBV combination treatment on the suppression of the development of HCC.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy of interferon‐beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C

Ikezaki

Nomura

Furusyo

et al. 2015

Hepatology Research

Self Cite

View full text Add to dashboard Cite

Aim: Although there is much evidence of an antitumor effect of pegylated interferon (IFN)-α-based treatment, limited data is available about that of IFN-β-based treatment. Our goal was to evaluate the impact of IFN-β plus ribavirin (RBV) treatment on the suppression of hepatocellular carcinoma (HCC).Methods: This retrospective, multicenter study consisted of 124 chronic hepatitis C patients who were treated with IFN-β plus RBV treatment, including 61 with advanced fibrosis and five with pretreatment HCC. All participants were followed for a median of 2.8 years (range, 2.2-3.2) after the end of their antiviral treatment. The data of 112 patients who finished the treatment were available for analysis. Cox proportional hazard analyses were performed to determine factors significantly associated with HCC development. Cumulative incidence curves for HCC were plotted using the Kaplan-Meier method and differences between groups were assessed using the log-rank test.Results: The 2.9% rate of HCC development of patients with sustained virological response (SVR) was significantly lower (P = 0.027) than the 15.9% of non-SVR patients. Interestingly, no significant difference was observed between the rates of HCC development of patients with and without advanced fibrosis (P = 0.733), even though the SVR rate of patients with advanced fibrosis was significantly lower than that of those without advanced fibrosis (P < 0.001).Stepwise multivariable Cox analysis extracted that only SVR was significantly associated with HCC development (hazard ratio, 0.20; 95% confidence interval, 0.03-0.84, P = 0.027).Conclusion: SVR was significantly associated with a lower risk of HCC development after IFN-β plus RBV treatment.

show abstract

Section: Discussionmentioning

confidence: 82%